NCT07599072 PREdiabetes GLycemic Impact and Data Evaluation
| NCT ID | NCT07599072 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nazarii Kobyliak |
| Condition | Pre Diabetic |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2026-05-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2026-05-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective, randomized controlled trial evaluates whether real-time continuous glucose monitoring (CGM) improves glycemic control and lifestyle adherence in adults with prediabetes compared to conventional self-monitoring methods over a 3-month period. By analyzing metabolic markers and behavioral data, the study aims to determine the effectiveness of 24-hour monitoring as a personalized tool that increases patient adherence to lifestyle changes compared to conventional SMBG methods.
Eligibility Criteria
Inclusion Criteria: * Age of 18 years and older. * Presence of prediabetes diagnosed according to criteria of the American Diabetes Association * Persons who treated with diet and exercise alone or metformin on a stabilized dose for at least 3 months before the study; * Ability to comply with protocol requirements and maintain a patient diary. * Signed informed consent. Exclusion Criteria: * Presence of type 1 or type 2 diabetes; * Decompensated liver or kidney diseases (GFR \< 45 ml/min/1. 73 m²); * Active cardiovascular diseases within 12 months of Visit 1, such as myocardial infarction, clinically significant arrhythmia, unstable angina, coronary artery bypass surgery, or angioplasty; or are expected to require coronary artery bypass surgery or angioplasty during the course of the study; * Endocrine disorders (e.g., Itsenko-Cushing syndrome, acromegaly) that affect glycemia; * Pregnancy or lactation; * Mental or cognitive impairments that would interfere with study participation; * Daily use of any form of steroid medication (oral, inhaled, injected) within the last 3 months; * Recent use of any CGM within the last 12 months; * Known allergy to sensor materials; * Has evidence of current abuse of drugs or alcohol or a history of abuse that, in the investigator's opinion, would cause the individual to be noncompliant; * Participation in another clinical study within the last 3 months.
Contact & Investigator
Nazarii Kobyliak
PRINCIPAL INVESTIGATOR
Bogomolets National Medical University
Frequently Asked Questions
Who can join the NCT07599072 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pre Diabetic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07599072 currently recruiting?
Yes, NCT07599072 is actively recruiting participants. Contact the research team at nazariikobyliak@gmail.com for enrollment information.
Where is the NCT07599072 trial being conducted?
This trial is being conducted at Kyiv, Ukraine, Kyiv, Ukraine.
Who is sponsoring the NCT07599072 clinical trial?
NCT07599072 is sponsored by Nazarii Kobyliak. The principal investigator is Nazarii Kobyliak at Bogomolets National Medical University. The trial plans to enroll 80 participants.